Small Molecules

17 Feb 2007 Roche files application in Europe for Tamiflu 30 and 45 mg capsules
17 Feb 2007 InSite Vision Announces License Agreement With Inspire Pharmaceuticals
17 Feb 2007 Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
16 Feb 2007 OXiGENE Announces Positive Results from its Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213)
16 Feb 2007 Positive Results with Lacosamide in Diabetic Neuropathic Pain in Phase III trial
16 Feb 2007 ARIAD Announces Global Phase 3 Clinical Trial Plans for AP23573 With Sarcoma Alliance and Achievement of Key Regulatory Milestones at Investor & Analyst Day
16 Feb 2007 FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for JANVUIA
16 Feb 2007 Alteon's Alagebrium Demonstrates Cardiovascular Activity In Recently Published Report Indicating Potential Wide-Ranging Benefits In Cardiovascular Diseases
16 Feb 2007 NanoBio(R) Corporation Initiates Phase 2b Clinical Trial for Herpes Labialis Treatment
16 Feb 2007 Elite Pharmaceuticals Provides Positive Clinical Update
15 Feb 2007 Activbiotics Announces Initiation Of Phase II Study In Carotid Atherosclerosis
15 Feb 2007 GW and Otsuka Announce Major Long Term Strategic Cannabinoid Alliance
15 Feb 2007 Pharmacopeia's DARA Program for Hypertension and Diabetic Nephropathy Advances Into Phase 1 Clinical Trials
15 Feb 2007 Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI-504 for Patients With Non-Small Cell Lung Cancer
14 Feb 2007 Rigel Announces Initiation of Phase 1 Study Evaluating R763 in Hematological Malignancies
14 Feb 2007 Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
14 Feb 2007 InSite Vision Announces Positive Top-Line Safety Results from Phase 1 AzaSite Plus Clinical Study
14 Feb 2007 Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment
14 Feb 2007 Somaxon Provides Update on SILENOR(TM) Preclinical Program
14 Feb 2007 SIGA Begins Second Human Safety Trial of Its Lead Smallpox Drug
14 Feb 2007 BioLineRx Successfully Completes Phase 1 Clinical Trials of BL-1020, First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
14 Feb 2007 Dynogen Reports Positive Results in Phase 2 IBS-c Study
14 Feb 2007 Elixir Pharmaceuticals and Siena Biotech S.p.A. Enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease
14 Feb 2007 Poniard Pharmaceuticals Files Investigational New Drug Application for Oral Formulation of Picoplatin
13 Feb 2007 Adolor Corporation Initiates Phase 1 Multi-Dose Study of Novel Delta Opioid Agonist for the Management of Pain

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top